Breaking News, Collaborations & Alliances

OcellO, Merus Enter Research Pact

To provide in vitro research services for Merus’ Phase I MCLA-158 Biclonics program

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

OcellO B.V., a Contract Research Organization offering 3D cell based assay services for drug discovery, has entered an agreement to provide in vitro research services to Merus N.V., a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, for Merus’ MCLA-158 Biclonics program. OcellO will provide €1 million of in vitro research services to Merus over a period of two years. OcellO will also utilize its 3D immune-oncology co-culture screening technology to support o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters